In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound-Reference-Cited by-同舟云学术

In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound

Published:2018-03-09 Issue:4 Volume:15 Page:1607-1617
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Kou Dawen^ORCID,Zhang Chen¹,Yiu Hiuwing,Ng Tania,Lubach Joseph W.^ORCID,Janson Matthew,Mao Chen,Durk Matthew,Chinn Leslie,Winter Helen,Wigman Larry,Yehl Peter

Affiliation:

1. Department of Chemistry, Michigan State University, 578 South Shaw Lane, East Lansing, Michigan 48824, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.7b01143

Reference46 articles.

1. The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC

2. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine

3. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: Case example nelfinavir

4. An In Vitro Methodology for Forecasting Luminal Concentrations and Precipitation of Highly Permeable Lipophilic Weak Bases in the Fasted Upper Small Intestine

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the impact of mucin on supersaturation and permeation of BCS class 2 basic drugs;Journal of Pharmaceutical Sciences;2024-08

2. Digitalizing the TIM-1 Model using Computational Approaches–Part One: TIM-1 Data Explorer;Molecular Pharmaceutics;2023-10-25

3. Comparative Evaluation of Particle Size Reduction, Salt Formation, and Amorphous Formulation on the Biopharmaceutical Performance of a Weak Base Drug Candidate;Molecular Pharmaceutics;2023-10-04

4. Progressive tools and critical strategies for development of best fit PBPK model aiming better in vitro–in vivo correlation;International Journal of Pharmaceutics;2023-08

5. Evaluating the bioequivalence of two pitavastatin calcium formulations based on IVIVC modeling and clinical study;Clinical and Translational Science;2022-10-17